Extensively drug-resistant (XDR) tuberculosis: An old and new threat

Annali dell'Istituto Superiore di Sanita

Volumn 43, Issue 4, 2007, Pages 317-319

  Fattorini, Lanfranco ^a   Migliori, Giovanni Battista ^b   Cassone, Antonio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b IRCCS   (Italy)

Author keywords

Drug resistance; Drug susceptibility testing; First line drugs; Mycobacterium tuberculosis; Second line drugs

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; DRUG EFFECT; HEALTH; HEALTH SURVEY; HUMAN; LUNG TUBERCULOSIS; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; PREVALENCE; TUBERCULOSIS, PULMONARY; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 38949110972     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. Geneva: WHO; 2003. (WHO/ TB/2003.320-WHO/CDS/ CSR/RMD/2003).
2. World Health Organization. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on anti-tuberculosis drug resistance surveillance. Geneva: WHO; 1997. (WHO/TB/97.229).
3. Toungoussova OS, Bjune G, Caugant DA. Epidemic of tuberculosis in the former Soviet Union: social and biological reasons. Tuberculosis 2006;86:1-10.
4. Pardini M, Iona E, Varaine F, Karakozian H, Arzumanian H, Brunori L, Orefici G, Fattorini L, the Long-Drug Study Group. Mycobacterium tuberculosis drug resistance, Abkhazia. Emerg Infect Dis 2005;11:501-3.
5. World Health Organization. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on anti-tuberculosis drug resistance surveillance. Geneva: WHO; 2004. (Report n. 3 WHO/HTM/TB/2004.343).
6. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR 2006;55:301-5.
7. Migliori GB, Centis R, Fattorini L, Besozzi G, Saltini C, Scarparo C, Cirillo D, Gori A, Cassone A, Piersimoni C. Mycobacterium tuberculosis complex drug resistance in Italy. Emerg Infect Dis 2004;10:752-3.
8. Kim SJ, Espinal MA, Abe C, Bai GH, Boulahbal F, Fattorini L, Gilpin C, Hoffner S, Kam KM, Martin-Casabona N, Rigouts L, Vincent V Is second-line anti-tuberculosis drug susceptibility testing reliable? Int J Tuberc Lung Dis 2004;8:1157-8.
9. Giannoni F, Iona E, Sementilli F, Brunori L, Pardini M, Migliori GB, Orefici G, Fattorini L. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49:2928-33.
10. Shah NS, Wright A, Drobniewski F, et al. Extreme drug resistance in tuberculosis ("XDR-TB"): Global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs. Int J Tuberc Lung Dis 2005;9(Suppl 1):S77.
11. Holtz TH, Riekstina V, Zarovska E, Laserson KF, Wells CD, Leimane V. XDR-TB: extreme drug-resistance and treatment outcome under DOTS-Plus, Latvia, 2000-2002. Int J Tuberc Lung Dis 2005;9(Suppl 1):S258.
12. Centers for Disease Control and Prevention (CDC). Extensively drug-resistant tuberculosis - United States, 1993-2006. MMWR 2007;56:250-3.
13. Raviglione MC, Smith IM. XDR tuberculosis - implications for global public health. N Engl J Med 2007;356:656-9.
14. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J 2007;29:423-7.
15. Masjedi MR, Farnia P, Sorooch S, Pooramiri MV, Mansoori SD, Zarifi AZ, Akbarvelayati A, Hoffner S. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis 2006;43:841-7.
16. Lumb R, Bastian I, Gilpin C, Jelfs P, Keehner T, Sievers A, Australian Mycobacterium Reference Laboratory Network. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2005. Commun Dis Intell 2007;31:80-6.
17. Migliori GB, Ortmann J. Girardi E, Besozzi G, Lange C, Cirillo DM, Ferrarese M, De laco G, Gori A, Raviglione M, and SMIRA/TBNET Study Group. Extensively drug-resistant tuberculosis, Italy and Germany. Emerging Infectious Diseases 2007;13:780-2.
18. Wise J. Southern Africa is moving swiftly to combat the threat of XDR-TB. Bull WHO 2006;84:924-5.
19. Kapp C. XDR tuberculosis spreads across South Africa. Lancet 2007;369:729.
20. Andrews J, Basu S, Scales D, Maru DS, Subbaraman R. XDR-TB in South Africa: theory and practice. PLoS Med 2007;4:770-1.
21. Goemaere E, Ford N, Berman D, McDermid C, Cohen R. XDR-TB in South Africa: Detention is not the priority. PLoS Med 2007;4:771-2.
22. Lawn SD, Wilkinson R. Extensively drug resistant tuberculosis. BMJ 2006;333:559-60.
23. Frieden TR, Sherman LF, Maw KL, Fujiwara PI, Crawford JT, Nivin B, Sharp V, Hewlett D Jr, Brudney K, Alland D, Kreisworth BN. A multi-institutional outbreak of highly drug-resistant tuberculosis: Epidemiology and clinical outcomes. JAMA 1996;276:1229-35.
24. Moro ML, Gori A, Errante I, Infuso A, Franzetti F, Sodano L, Iemoli E, Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy, AIDS 1998;12:1095-102.